Hereditary cancer syndromes

Journal of B.U.ON.

Volumn 12, Issue SUPPL. 1, 2007, Pages

  Fostira, Florentia ^a,b   Thodi, Georgia ^a,b   Konstantopoulou, Irene ^a   Sandaltzopoulos, Raphael ^b   Yannoukakos, Drakoulis ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

BRCA; FAP; Hereditary cancer syndromes; HNPCC

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CELECOXIB; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; TAMOXIFEN;

ADENOMATOUS POLYP; AUTOSOMAL RECESSIVE INHERITANCE; BREAST CANCER; CANCER GENETICS; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; CONFERENCE PAPER; ENVIRONMENTAL FACTOR; FAMILIAL CANCER; FAMILY HISTORY; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEREDITY; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; MISMATCH REPAIR; ONSET AGE; OVARY CANCER; PHENOTYPE; PRIMARY HEALTH CARE; PROCTOCOLECTOMY; SALPINGOOOPHORECTOMY; SURVIVAL RATE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOMATOUS POLYPOSIS COLI; BREAST NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MALE; MUTS HOMOLOG 2 PROTEIN; NEOPLASTIC SYNDROMES, HEREDITARY; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PEDIGREE; PHENOTYPE; RISK FACTORS;

EID: 36749031683     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919-31.
2. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999; 91: 916-932.
3. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57: 1457-1462.
4. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004; 4: 769-780.
5. Jarvinen HJ. Hereditary cancer: guidelines in clinical practice. colorectal cancer genetics. Ann Oncol 2004; 15 (Suppl 4): iv127-131.
6. Peltomaki P, Vasen H. Mutations associated with HNPCC predisposition - Update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 2004; 20: 269-276.
7. Plaschke J, Engel C, Kruger S et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: The German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol 2004; 22: 4486-4494.
8. Pinto C, Veiga I, Pinheiro M et al. MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease. Br J Cancer 2006; 95: 752-756.
9. Barnetson RA, Tenesa A, Farrington SM et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006; 354: 2751-2763.
10. Domingo E, Niessen RC, Oliveira C et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005; 24: 3995-3998.
11. Domingo E, Laiho P, Ollikamen M et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004: 41: 664-668.
12. Ford JM, Whittemore AS. Predicting and preventing hereditary colorectal cancer. JAMA 2006; 296: 1521-1523.
13. Balmana J, Stockwell DH, Steyerberg EW et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 2006; 296: 1469-1478.
14. Chen S, Wang W, Shing L et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006; 296: 1479-1487.
15. Kinzler KW, Nilbert MC, Su LK et al. Identification of FAP locus genes from chromosome 5q21. Science 1991; 253: 661-665.
16. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001; 10: 721-733.
17. Nishisho I, Nakamura Y, Miyoshi Y et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991; 253: 665-669.
18. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006; 101: 385-398.
19. Ficari F, Cama A, Valanzano R et al. APC gene mutations and colorectal adenomatosis in familial adenomatous polyposis. Br J Cancer 2000; 82: 348-353.
20. Truta B, Allen BA, Conrad PG et al. Genotype and phenotype of patients with both familial adenomatous polyposis and thyroid carcinoma. Fam Cancer 2003; 2: 95-99.
21. Giardiello, FM, Petersen GM, Brensinger JD et al. Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. Gut 1996; 39: 867-873.
22. Arvanitis ML, Jagelman DG, Fazio VW et al. Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 1990; 33: 639-642.
23. Bisgaard ML, Bulow S. Familial adenomatous polyposis (FAP): genotype correlation to FAP phenotype with osteomas and sebaceous cysts. Am J Med Genet 2006; 140: 200-204.
24. Attard TM, Giglio P, Koppula S, Snyder C, Lynch HT. Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. Cancer 2007; 109: 761-766.
25. Shields CL, Mashayekhi A, Ho T et al. Solitary congenital hypertrophy of the retinal pigment epithelium: clinical features and frequency of enlargement in 330 patients. Ophthalmology 2003; 110: 1968-1976.
26. Lynch HT, Smyrk T, McGinn T et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer 1995; 76: 2427-2433.
27. Sampson JR, Jones S, Dolwani S, Cheadle JP. MutYH (MYH) and colorectal cancer. Biochem Soc Trans 2005; 33: 679-683.
28. Caspari R, Olschwang S, Friedl W et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 1995; 4: 337-340.
29. Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952.
30. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A. Effectiveness of preventive interventions in BRCA 1/2 gene mutation carriers: A systematic review. Int J Cancer 2007; 121: 225-231.
31. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4: 665-676.
32. James PA, Doherty R, Harris M et al. Optimal selection of individuals for BRCA mutation testing: A comparison of available methods. J Clin Oncol 2006; 24: 707-715.
33. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348: 2339-2347.
34. Chen S, Parmigianni G. Meta-analysis of BRCA1 and BRCA2 penetrance, J Clin Oncol 2007; 25: 1329-1333.
35. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell 2007; 11: 103-105.
36. Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-1093.
37. Cox A, Dunning AM, Garcia-Closas M et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007; 39: 352-358.
38. Konstantopoulou I, Rampias T, Ladopoulou A et al. Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers among high-risk breast/ovarian cancer patients. Breast Cancer Res Treat 2007; Apr 24 [Epub ahead of print].
39. Armaou S, Konstantopoulou I, Anagnostopoulos T et al. Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients. Eur J Cancer 2007; 43: 443-453.
40. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991; 48: 232-242.
41. Claus RB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994; 73: 643-651.
42. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
43. Fasching PA, Bani MR, Nestle-Kramling C et al. Evaluation of mathematical models for breast cancer risk assessment in routine clinical use. Eur J Cancer Prev 2007; 16: 216-224.
44. Foulkes WD. BRCA1 and BRCA2: Chemosensitivity, treatment, outcomes and prognosis. Fam Cancer 2006; 5: 135-142.
45. Moller P, Evans DG, Reis MM et al. Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer 2007; 121: 1017-1020.